



US009744181B2

(12) **United States Patent**
Dahl et al.

(10) **Patent No.:** **US 9,744,181 B2**
(45) **Date of Patent:** ***Aug. 29, 2017**

(54) **COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY**

(71) Applicant: **Gilead Sciences, Inc.**, Foster City, CA (US)

(72) Inventors: **Terrence C. Dahl**, Sunnyvale, CA (US); **Mark M. Menning**, San Francisco, CA (US); **Reza Oliyai**, Foster City, CA (US)

(73) Assignee: **Gilead Sciences, Inc.**, Foster City, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/523,783**

(22) Filed: **Oct. 24, 2014**

(65) **Prior Publication Data**

US 2015/0111856 A1 Apr. 23, 2015

Related U.S. Application Data

(63) Continuation of application No. 14/227,653, filed on Mar. 27, 2014, which is a continuation of application No. 12/204,174, filed on Sep. 4, 2008, now Pat. No. 8,716,264, which is a continuation of application No. 10/540,794, filed as application No. PCT/US2004/000832 on Jan. 13, 2004, now abandoned.

(60) Provisional application No. 60/440,246, filed on Jan. 14, 2003, provisional application No. 60/440,308, filed on Jan. 14, 2003.

(51) **Int. Cl.**

A61K 9/20 (2006.01)

A61K 31/675 (2006.01)

A61K 31/513 (2006.01)

A61K 31/7076 (2006.01)

A61K 45/06 (2006.01)

A61K 31/683 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/675** (2013.01); **A61K 9/2009** (2013.01); **A61K 9/2013** (2013.01); **A61K 9/2018** (2013.01); **A61K 9/2054** (2013.01); **A61K 9/2059** (2013.01); **A61K 31/513** (2013.01); **A61K 31/683** (2013.01); **A61K 31/7076** (2013.01); **A61K 45/06** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,524,846 A 8/1970 Moffatt et al.
3,622,677 A 11/1971 Short et al.

3,682,930 A 8/1972 Bourquin et al.
3,994,974 A 11/1976 Murakami et al.
4,003,878 A 1/1977 Skaar et al.
4,258,062 A 3/1981 Jonas et al.
4,355,032 A 10/1982 Verheyden et al.
4,384,005 A 5/1983 McSweeney
4,430,343 A 2/1984 Iemura et al.
4,476,248 A 10/1984 Gordon et al.
4,724,233 A 2/1988 De Clercq et al.
4,808,716 A 2/1989 Holy et al.
4,816,570 A 3/1989 Farquhar
4,879,288 A 11/1989 Warawa et al.
4,935,507 A 6/1990 Takaya et al.
4,957,924 A 9/1990 Beauchamp
4,968,788 A 11/1990 Farquhar
5,047,407 A 9/1991 Belleau et al.
5,075,445 A 12/1991 Jarvest et al.
5,142,051 A 8/1992 Holy et al.
5,151,426 A 9/1992 Belleau et al.
5,155,268 A 10/1992 Hester
5,177,064 A 1/1993 Bodor
5,179,104 A 1/1993 Chu et al.
5,204,466 A 4/1993 Liotta et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP 0 182 024 A2 5/1986
EP 0 206 459 A2 12/1986

(Continued)

OTHER PUBLICATIONS

Decision Denying Petitioner's Request for Rehearing for Case PTAB-IPR2014-00885, dated Aug. 3, 2015, 15 pages.

Decision Denying Petitioner's Request for Rehearing for Case PTAB-IPR2014-00887, dated Aug. 3, 2015, 13 pages.

Decision Denying Petitioner's Request for Rehearing for Case PTAB-IPR-2014-00888, dated Aug. 3, 2015, 15 pages.

Joint Motion to Dismiss and Stipulation by Mylan Inc., Mylan Pharmaceuticals Inc., Case No. 1:14-cv-00099-IMF-JSK (Dated: Oct. 30, 2015), 3 pages.

Order on Stipulation for Dismissal: Ordered, adjudged and decreed that all claims, counterclaims or causes of action asserted in this suit by and between Gilead, Emory and Mylan are dismissed with prejudice. Signed by District Judge Irene M. Keeley on Nov. 2, 2015. (jss), Case No. 1:14-cv-00099-IMF-JSK (Entered: Nov. 2, 2015), 2 pages.

(Continued)

Primary Examiner — Alton Pryor

(74) Attorney, Agent, or Firm — Fish & Richardson P.C.

(57)

ABSTRACT

The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (–)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.

30 Claims, No Drawings